Tissue transglutaminase antibodies in celiac disease

F. Biagi, H. J. Ellis

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

OBJECTIVE: Tissue transglutaminase is the antigen for antiendomysial antibodies, whose power in screening for celiac disease is well known. Our aim was to assess the efficacy of an ELISA assay for tissue transglutaminase antibodies. METHODS: Tissue transglutaminase antibodies were analyzed in serum from 39 untreated celiac disease patients and 61 controls. Tissue transglutaminase was used as antigen, and test sera analyzed by ELISA. Results higher than 0.6 optical density were considered positive, lower than 0.4 negative, and between 0.4 and 0.6 borderline. RESULTS: Optical density of the serum from the patients with untreated celiac disease (median: 1.41; range: 0.331.47) were significantly higher than the controls (median: 0.32; range: 0.17-0.68; p <0.0001; 95% confidence interval 0.87-1.08). Thirty- three patients with untreated celiac disease were positive, 4 borderline, and 2 negative. Fifty-five controls were negative, 4 borderline, and 2 positive. If we consider borderline results to be positive, sensitivity is 94.8% and specificity 90.1%. None of the controls gave results higher than 0.7 optical density. Apart from the 2 negative patients with untreated celiac disease, the two groups overlapped only between 0.4 and 0.7 optical density. CONCLUSIONS: Because of the high sensitivity (≃95%) and technical simplicity, tissue transglutaminase antibodies may prove useful for the screening of celiac disease in population at low or medium risk of celiac disease. To avoid duodenal biopsies in patients without celiac disease, the specificity of the screening procedure may be increased by confirming with antiendomysial antibodies by immunofluorescence on human umbilical cord in individuals with results between 0.4 and 0.7 optical density.

Original languageEnglish
Pages (from-to)2187-2192
Number of pages6
JournalAmerican Journal of Gastroenterology
Volume94
Issue number8
DOIs
Publication statusPublished - Aug 1999

Fingerprint

Celiac Disease
Antibodies
Serum
Enzyme-Linked Immunosorbent Assay
Antigens
transglutaminase 2
Umbilical Cord
Fluorescent Antibody Technique
Confidence Intervals
Biopsy
Population

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Tissue transglutaminase antibodies in celiac disease. / Biagi, F.; Ellis, H. J.

In: American Journal of Gastroenterology, Vol. 94, No. 8, 08.1999, p. 2187-2192.

Research output: Contribution to journalArticle

@article{06a5fd7a77ae43efa39d601f5f590a9d,
title = "Tissue transglutaminase antibodies in celiac disease",
abstract = "OBJECTIVE: Tissue transglutaminase is the antigen for antiendomysial antibodies, whose power in screening for celiac disease is well known. Our aim was to assess the efficacy of an ELISA assay for tissue transglutaminase antibodies. METHODS: Tissue transglutaminase antibodies were analyzed in serum from 39 untreated celiac disease patients and 61 controls. Tissue transglutaminase was used as antigen, and test sera analyzed by ELISA. Results higher than 0.6 optical density were considered positive, lower than 0.4 negative, and between 0.4 and 0.6 borderline. RESULTS: Optical density of the serum from the patients with untreated celiac disease (median: 1.41; range: 0.331.47) were significantly higher than the controls (median: 0.32; range: 0.17-0.68; p <0.0001; 95{\%} confidence interval 0.87-1.08). Thirty- three patients with untreated celiac disease were positive, 4 borderline, and 2 negative. Fifty-five controls were negative, 4 borderline, and 2 positive. If we consider borderline results to be positive, sensitivity is 94.8{\%} and specificity 90.1{\%}. None of the controls gave results higher than 0.7 optical density. Apart from the 2 negative patients with untreated celiac disease, the two groups overlapped only between 0.4 and 0.7 optical density. CONCLUSIONS: Because of the high sensitivity (≃95{\%}) and technical simplicity, tissue transglutaminase antibodies may prove useful for the screening of celiac disease in population at low or medium risk of celiac disease. To avoid duodenal biopsies in patients without celiac disease, the specificity of the screening procedure may be increased by confirming with antiendomysial antibodies by immunofluorescence on human umbilical cord in individuals with results between 0.4 and 0.7 optical density.",
author = "F. Biagi and Ellis, {H. J.}",
year = "1999",
month = "8",
doi = "10.1111/j.1572-0241.1999.01292.x",
language = "English",
volume = "94",
pages = "2187--2192",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Tissue transglutaminase antibodies in celiac disease

AU - Biagi, F.

AU - Ellis, H. J.

PY - 1999/8

Y1 - 1999/8

N2 - OBJECTIVE: Tissue transglutaminase is the antigen for antiendomysial antibodies, whose power in screening for celiac disease is well known. Our aim was to assess the efficacy of an ELISA assay for tissue transglutaminase antibodies. METHODS: Tissue transglutaminase antibodies were analyzed in serum from 39 untreated celiac disease patients and 61 controls. Tissue transglutaminase was used as antigen, and test sera analyzed by ELISA. Results higher than 0.6 optical density were considered positive, lower than 0.4 negative, and between 0.4 and 0.6 borderline. RESULTS: Optical density of the serum from the patients with untreated celiac disease (median: 1.41; range: 0.331.47) were significantly higher than the controls (median: 0.32; range: 0.17-0.68; p <0.0001; 95% confidence interval 0.87-1.08). Thirty- three patients with untreated celiac disease were positive, 4 borderline, and 2 negative. Fifty-five controls were negative, 4 borderline, and 2 positive. If we consider borderline results to be positive, sensitivity is 94.8% and specificity 90.1%. None of the controls gave results higher than 0.7 optical density. Apart from the 2 negative patients with untreated celiac disease, the two groups overlapped only between 0.4 and 0.7 optical density. CONCLUSIONS: Because of the high sensitivity (≃95%) and technical simplicity, tissue transglutaminase antibodies may prove useful for the screening of celiac disease in population at low or medium risk of celiac disease. To avoid duodenal biopsies in patients without celiac disease, the specificity of the screening procedure may be increased by confirming with antiendomysial antibodies by immunofluorescence on human umbilical cord in individuals with results between 0.4 and 0.7 optical density.

AB - OBJECTIVE: Tissue transglutaminase is the antigen for antiendomysial antibodies, whose power in screening for celiac disease is well known. Our aim was to assess the efficacy of an ELISA assay for tissue transglutaminase antibodies. METHODS: Tissue transglutaminase antibodies were analyzed in serum from 39 untreated celiac disease patients and 61 controls. Tissue transglutaminase was used as antigen, and test sera analyzed by ELISA. Results higher than 0.6 optical density were considered positive, lower than 0.4 negative, and between 0.4 and 0.6 borderline. RESULTS: Optical density of the serum from the patients with untreated celiac disease (median: 1.41; range: 0.331.47) were significantly higher than the controls (median: 0.32; range: 0.17-0.68; p <0.0001; 95% confidence interval 0.87-1.08). Thirty- three patients with untreated celiac disease were positive, 4 borderline, and 2 negative. Fifty-five controls were negative, 4 borderline, and 2 positive. If we consider borderline results to be positive, sensitivity is 94.8% and specificity 90.1%. None of the controls gave results higher than 0.7 optical density. Apart from the 2 negative patients with untreated celiac disease, the two groups overlapped only between 0.4 and 0.7 optical density. CONCLUSIONS: Because of the high sensitivity (≃95%) and technical simplicity, tissue transglutaminase antibodies may prove useful for the screening of celiac disease in population at low or medium risk of celiac disease. To avoid duodenal biopsies in patients without celiac disease, the specificity of the screening procedure may be increased by confirming with antiendomysial antibodies by immunofluorescence on human umbilical cord in individuals with results between 0.4 and 0.7 optical density.

UR - http://www.scopus.com/inward/record.url?scp=0033179791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033179791&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.1999.01292.x

DO - 10.1111/j.1572-0241.1999.01292.x

M3 - Article

C2 - 10445548

AN - SCOPUS:0033179791

VL - 94

SP - 2187

EP - 2192

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -